iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
SVR in HIV/HCV Coinfected / DDIs
 
 
  8 weeks - A5327 Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1-infected Individuals (SWIFT-C) - (10/24/17)
 
EASL: THERAPY WITH DIRECT ANTIVIRAL AGENTS IN PATIENTS WITH HCV-RELATED LYMPHOPROLIFERATIVE DISORDERS AND MIXED CRYOGLOBULINEMIA - (04/26/17)
 
EASL: Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected With Hepatitis C Virus and Human Immunodeficiency Virus-1: The EXPEDITION-2 Study - (04/20/17)
 
EASL: Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: The ASTRAL-5 Study - (04/18/16)
 
CROI: GLECAPREVIR AND PIBRENTASVIR INTERACTIONS WITH COMBINATION ANTIRETROVIRAL REGIMENS - (02/20/17)
 
Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir and Velpatasvir (GS-5816) and HIV Antiretoviral Therapies - (12/08/15)
 
EASL: Drug-Drug Interaction Profile of Sofosbuvir/Velpatasvir Fixed-Dose Combination - (04/21/16)
 
New HCV Drug Approvals - studies - (09/22/17)

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org